References
- Oner AF, Ferahbas A, Karakucuk S, et al. Ocular side effects associated with systemicisotretinoin. Cutan Ocul Toxicol. 2005;23:189–95.
- Egger SF, Huber-Spitzy V, Böhler K, Scholda C. Isotretinoin administration in treatmentof acne vulgaris: a prospective study of the kind and extent of ocularcomplications. Ophthalmologe. 1995;92:17–20.
- Egger SF, Huber-Spitzy V, Böhler K, et al. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilmand conjunctival flora. Acta Ophthalmol Scand. 1995;73:355–7.
- Bozkurt B, Irkec MT, Atakan N, et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002;12:173–6.
- Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132:299–305.
- Fraunfelder FW. Ocular side effects associated with isotretinoin. Drugs Today (Barc). 2004;40:23–7.
- Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring andtreatment algorithm for clinicians. Drug Saf. 2010;33:25–34.
- Danby FW. Oral isotretinoin, neuropathy and hypovitaminosis A. Clin Exp Dermatol. 2009;34:260.
- Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008;27:197–206.
- Aydogan K, Turan OF, Onart S, et al. Neurological and neurophysiological effects of oral isotretinoin: a prospective investigation using auditory and visual evoked potentials. Eur J Dermatol. 2008;18:642–6.
- Dinc UA, Yenerel NM, Gorgun E, et al. A case with bilateral optic nerve atrophy associated with isotretinoin treatment for acne vulgaris. TOD J. 2009;39:60–3.
- Rebolleda G, Diez-Alvarez L, Casado A, et al. OCT: new perspectives in neuro-ophthalmology. Saudi J Ophthalmol. 2015;29:9–25.
- Grewal DS, Tanna AP. Diagnosis of glaucoma and detection of glaucoma progression using spectral domain optical coherence tomography. Curr Opin Ophthalmol. 2013;24:150–61.
- Sekeryapan B, Dılek N, Oner V. Retinal nerve fiber layer and ganglion cell layer thickness in patients receiving systemic isotretinoin therapy. Int Ophthalmol. 2013;33:481–4.
- Kaptı BH, Aslan G, Yavruoğlu MA. Evaluation of retinal nerve fiber layer changes with oral isotretinoin treatment. Ophthalmol Ther. 2013;2:19–23.
- Ucak H, Aykut V, Ozturk S, et al. Effect of oral isotretinoin treatment on retinal nerve fiber layer thickness. J Cutan Med Surg. 2014;18:236–42.
- Nencini C, Barberi L, Runci FM, Micheli L. Retinopathy induced by drugs and herbal medicines. Eur Rev Med Pharmacol Sci. 2008;12:2938.
- Campochiaro PA, Hackett SF, Conway BP. Retinoic acid promotes density dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1991;32:65.
- Sieving PA, Chaudhry P, Kondo M, et al. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci USA. 2001;1398:1835–40.